Clinical Trials · NCT07502508
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Biomea Fusion Inc.
- Enrollment
- 60
- Start date
- Apr 2026
- Locations
- 17 sites, United States
- Primary endpoint
- To demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic control